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Abstract 
The study aimed to examine symptoms of hypochondriasis in relation to obsessive-
compulsive disorder (OCD), by investigating the prevalence of hypochondriacal symptoms in 
OCD, the effect hypochondriacal symptoms has on OCD treatment outcome, and how OCD 
treatment affects hypochondriacal symptoms. Another objective of the study was to explore 
the role of metacognition in symptoms of hypochondria. A sample of 313 patients with a 
primary diagnosis of OCD and 382 community controls were compared on the Whiteley 
Index of hypochondriasis, the Metacognitions Questionnaire, and the Yale-Brown Obsessive-
Compulsive Scale. Results showed that the prevalence of hypochondriasis symptoms was 
30.7% in the OCD sample, significantly higher than in the control group. Furthermore, 
symptoms of hypochondria did not have a significant effect on OCD treatment outcome. 
Hypochondriacal symptoms improved moderately following OCD treatment. Finally, 
symptoms of hypochondriasis were found to be moderately correlated with metacognition and 
improvement in hypochondriasis was associated with changes in metacognitive beliefs. 
Implications for treatment and future research is discussed. 
 Keywords: hypochondriasis, obsessive-compulsive disorder, comorbidity, and 
metacognition. 
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Hypochondriasis describes a condition were one is preoccupied with fears and ideas of having 
a serious disease due to misinterpretation of somatic symptoms (American Psychiatric 
Association [APA], 1994). The preoccupation lasts for at least six months and persists despite 
medical reassurance that there is no underlying disease warranting the experienced distress. 
Because those who have hypochondria are usually disinclined to regard their problems as 
anything other than physical, they typically surface in primary and specialty medical settings 
rather than in psychiatric clinics. Moreover, they usually make frequent telephone inquiries 
and office visits concerning relatively minor or undetectable symptoms, seeking constant 
reassurance that they are not severely ill (Abramowitz, 2005). The prevalence of 
hypochondriasis in the normal population is unknown, but in general medical practice it has 
been reported to be between 4 and 9% (APA, 1994). The relatively high prevalence rate, 
reluctance to accept referral to psychiatric clinics, and excessive health care utilization have 
made hypochondriacs a social concern both from a public health, and cost effectiveness 
perspective (Greeven et al., 2007).  
For a long time, hypochondriasis had a reputation of being chronic and relatively 
refractory to treatment (Greeven et al., 2007). However, relatively recent advances in 
cognitive-behavioral conceptualizations have lead to more effective management (Beck, 
Emery, & Greenberg, 1985; Bouman & Visser, 1998; Speckens et al., 1995; Warwick & 
Salkovskis, 1990). According to the cognitive-behavioral model, a hypochondriacal “loop” 
starts out with bodily sensations triggering catastrophic misinterpretations. These 
misinterpretations are hypothesized to elicit anxiety. The anxiety is in turn assumed to initiate 
maladaptive hypochondriacal behavior such as checking, reassurance seeking, and avoidance 
of disease related stimuli. Furthermore, hypochondriacal behavior is thought to result in 
selective attention towards bodily sensations and disease-related stimuli, which further 
increases anxiety and causes more bodily symptoms. Essentially, the hypochondriac ends up 
being caught in a vicious circle where the problem is maintained by erroneous beliefs about 
health as well as maladaptive behavioral responses. Cognitive-behavioral therapy (CBT) is 
currently established as the leading treatment for hypochondriasis (Kroenke, 2007; 
Seivewright et al., 2008). Predominantly, CBT treatment constitutes techniques helping 
patients recognize and modify erroneous beliefs about illness, such as “all bodily sensations 
are signs of serious illness” (Abramowitz, 2005). Furthermore, CBT attempts to eliminate 
behavioral responses considered barriers to self-correction of faulty beliefs.  
The observation of overlapping features in hypochondriasis and obsessive-compulsive 
disorder (OCD) has resulted in an upsurge of interest in how the two disorders are related 
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(Savron et al., 1996). OCD is characterized by the presence of obsessions and compulsions 
(APA, 1994). An obsession is a thought, image or impulse that repeatedly appears in a 
person’s consciousness in a stereotypic form. Obsessions are experienced as anxiety 
provoking because their content is usually violent or obscene, or perceived as meaningless. 
Examples of obsessions are impulses to harm one’s own children, and thoughts of 
contamination. The person experiencing obsessions usually attempts to ignore or neutralize 
them by respectively avoiding triggers, using thought suppression, or performing a 
compulsion. A compulsion is a specific behavior or mental act, which has to be performed in 
a rigid manner in response to an obsession. Examples of compulsive behaviors are checking, 
ordering, and washing, while compulsive mental acts can be counting, praying, or silently 
repeating words. The purpose of a compulsion is to prevent anxiety or a feared event from 
happening, both usually having their origin in a previous obsession. However, the behavioral 
or mental act of a compulsion will usually be either clearly excessive or not realistically 
designed considering what the person wants to prevent.  
Hypochondriasis resembles OCD in that anxiety is evoked by specific reoccurring 
intrusive thoughts or ideas and reduced by ritualistic reassurance seeking, and symptom 
checking (Fallon, Javitch, Hollander, & Liebowitz, 1991; Neziroglu, McKay, &Yaryura-
Tobias, 2000; Warwick & Salkovskis, 1990). Furthermore, patients with OCD often fear 
illness, injury or contamination, which is considered the core theme of the hypochondriasis 
diagnosis (Savron et al., 1996). In fact, 55% of OCD patients have been reported to have 
contamination obsessions, while 34% are suggested to have somatic obsessions (e.g. fear of 
breast cancer, with a resulting compulsion to check for this) (Rasmussen & Tsuang, 1986). 
Furthermore, 47.6% of OCD patients conduct washing/cleaning compulsions (Ball, Baer, & 
Otto, 1996) typically associated with contamination-related obsessions (Tolin & Meunier, 
2008).  
However, there are also important differences distinguishing hypochondriasis and 
OCD. The main differences is that obsessions related to illness and disease are typically 
characterized by fear of getting sick in the future, rather than having become ill already, 
which is the hypochondriac’s conviction (Fallon, Klein, & Liebowitz, 1993). Also, OCD 
patients generally have more insight in their illness than hypochondriacs, being aware that 
their thoughts and actions are unrealistic (Neziroglu et al., 2000).  
The similarities and differences between hypochondriasis and OCD have resulted in a 
debate regarding whether they’re related or not. In conjunction with this, it’s discussed if 
hypochondriasis might be best defined as a subtype of OCD (focused on illness fears and 
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bodily sensations), or should belong to the obsessive-compulsive spectrum, which is a 
collective term for disorders seemingly closely related to OCD (Fallon et al., 1991; Fallon, 
Qureshi, Laje, & Klein, 2000; Neziroglu et al., 2000). These questions have lead to 
substantial research in the field addressing the link between hypochondriasis and OCD, and 
possible treatment implications of a potential connection. In particular, research has addressed 
whether what we know about treating OCD can be of help in curing hypochondria, because 
treatment research and success was obtained in OCD prior to that of hypochondriasis (Fallon 
et al., 1993). Conducting studies on hypochondriasis applying methods found effective in 
OCD treatment has been profitable and to a great extent contributed to our current knowledge 
base of hypochondriasis (Neziroglu et al., 2000).  
 
Prevalence of symptoms of hypochondriasis in patients with OCD 
Patterns of comorbidity between hypochondriasis and OCD are among the central 
matters in research addressing the relationship between the two (Fallon et al., 2000; Neziroglu 
et al., 2000; Savron et al., 1996). Most studies have investigated prevalence rate of OCD in 
patients with hypochondriasis rather than the reverse comorbidity. Currently, findings on the 
prevalence of hypochondria in OCD patients are inconclusive, but the most recent and 
methodological robust studies suggest a prevalence rate of 13-15%, significantly higher than 
that in controls.  
One Indian study investigating the prevalence of hypochondriasis in 231 OCD 
subjects (Jaisoorya, Janardhan Reddy, & Srinath, 2003), revealed a significantly higher 
prevalence among the clinical sample compared with a control group consisting of relatives to 
neurologically ill patients (n = 200). Here, the prevalence rate in OCD patients was found to 
be 13%, while 0% of the controls exhibited symptoms of hypochondria. In their study, adults 
and children were mixed. Adult patients and controls were assessed for hypochondriasis using 
the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), and the children 
were measured by means of the Schedule for Affective Disorders and Schizophrenia for 
School-Age Children (K-SADS).   
Another study examining the relationship of OCD to possible spectrum disorders, 
found similar results as the study from India mentioned above (Bienvenu et al., 2000). Results 
revealed that the prevalence of hypochondriasis was significantly higher in a group of 80 
patients with OCD compared to 73 healthy controls. Hypochondriasis was measured using the 
Schedule for Affective Disorders and Schizophrenia - Lifetime Anxiety Version, while 
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collateral information for diagnostic evaluation was gathered from knowledgeable informants 
associated to each subject. The lifetime prevalence of hypochondriasis was reported to be 
15% in the OCD patient sample, and 0% in the control group. Additionally, hypochondriasis 
occurred more frequently in first-degree relatives with OCD, regardless of whether case 
probands had hypochondriasis or not. 
Two studies with smaller sample sizes have found different results. One trial measured 
hypochondriacal symptoms by administering the subscale “hypochondriac beliefs” – a part of 
the Illness Attitude Scale to 30 patients with DSM-IV OCD and 30 socio-demographically 
similar controls (Savron et al., 1996). In this study, three from the patient group (10%) and 
two from the control group (6.67%) displayed characteristic hypochondriacal responses. 
Furthermore, unpublished observations also found that the hypochondriasis prevalence rate in 
OCD patients was not significantly different from that of controls (Fallon et al., 2000). Here, 
the Whiteley Index (WI) was administered to 17 patients with DSM-III-R hypochondriasis, 
21 with DSM-III-R OCD, and 24 controls. As expected, hypochondriasis patients had a 
significantly higher degree of hypochondria than both OCD patients and controls. Comparing 
the results for the OCD patients and controls, patients with OCD had a 16.7% prevalence rate 
of hypochondriasis, not significantly greater than the 10% prevalence rate found in controls. 
The applied cutoff score was not accounted for. 
In summary, previous research show that prevalence rates of hypochondriacal 
symptoms in patients with OCD range from 10 to 16.7%. Only half of the existing studies 
suggest a significantly greater prevalence rate in OCD patients compared to controls, possibly 
due to limited sample sizes.  Finding out whether symptoms of hypochondriasis are more 
common amongst those with OCD, and identifying the exact hypochondriacal symptoms 
prevalence rate in the OCD group is important for a better understanding of both 
hypochondriasis and OCD. Furthermore, prevalence findings can imply what future research 
is needed. If the prevalence is established to be high, it will be necessary to further examine 
how hypochondriasis and OCD affect each other, whether they can be explained by common 
mechanisms, and how knowledge on these matters can contribute to efficient treatment.  
 
Do symptoms of hypochondria affect OCD treatment outcome? 
Empirical research show that the presence of comorbid disorders in mental illness may 
affect treatment response negatively by adding to patient distress (Abramowitz, Franklin, 
Street, Kozak, & Foa, 2000). Looking at OCD in particular, most patients with OCD have at 
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least one co-morbid mental disorder (Steketee, 1993), and at least 50% have a comorbid axis I 
disorder (Tükel, Polat, Özdemir, Aksüt, & Türksoy, 2002). Comorbid conditions in OCD 
have been found to raise anxiety and depression levels in OCD patients, and most 
importantly, the severity of obsessions and compulsions, as well as lowering patient insight 
(Tükel et al., 2002). In compliance with these findings, those who are non-responsive to OCD 
treatment are more likely to meet criteria for comorbid axis I or axis II disorders (Pallanti et 
al, 2002).  
The effect of comorbid symptoms of hypochondria on OCD treatment outcome has 
never been examined. However, previous studies have addressed treatment effects of several 
other coexisting mental disorders. Overall, comorbid severe depression (Abramowitz et al., 
2000; Keeley, Storch, Merlo, & Geffken, 2008; Steketee, Chambless, & Tran, 2001), 
generalized anxiety disorder (Hansen, Vogel, Stiles, & Götestam, 2007; Steketee et al., 2001), 
and panic disorder (Hansen et al., 2007) seem related to poorer OCD treatment outcome. 
Results regarding comorbid personality disorders are somewhat inconclusive, but it seems 
that especially schizotypal personality disorder hinder the treatment of OCD (Baer et al., 
1992; Cavedini et al., 1997; Dreessen, Hoekstra, & Arntz, 1997; Fricke et al., 2006; Haan et 
al., 1997; Hansen et al., 2007; Moritz et al., 2004). Finally, comorbid tic disorder does not 
seem to influence the outcome of OCD treatment (Himle, Fischer, Van Etten, Janeck, & 
Hanna, 2003). In general, it seems like some comorbid disorders could have a negative effect 
on OCD treatment response. Nevertheless, it remains unknown how results of OCD treatment 
are affected by symptoms of hypochondriasis in particular. 
 
Changes in hypochondriacal symptoms following OCD treatment 
Treatment studies have never addressed whether OCD treatment affects 
hypochondriacal symptoms. However, a variety of treatment trials have been conducted to see 
if effective OCD treatment strategies adapted to address hypochondriacal symptoms are 
effective for hypochondriasis (Fallon et al., 1993). Looking into existing research on 
hypochondriasis, cognitive-behavioral strategies applied effectively in OCD treatment 
(Marks, 1981; Salkovskis & Warwick, 1985) have been successfully implemented in the 
treatment of hypochondriacal patients (Fallon et al., 1993; Salkovskis & Warwick, 1986; 
Warwick, Clark, Cobb, & Salkovskis, 1996; Warwick & Salkovskis, 1989; Yaryura-Tobias & 
Neziroglu, 1997). Although previous studies have tried out treatments of hypochondriasis 
inspired by strategies from OCD treatment, hypochondriacs have traditionally been treated 
SYMPTOMS OF HYPOCHONDRIA IN OCD 
	  
9	  
with manuals adapted specifically to hypochondriasis. Moreover, several studies suggest that 
pharmacotherapy reduce hypochondriacal symptoms when applying dosage levels of 
serotonergic medication originally modeled after studies of OCD (Bodkin & White, 1989; 
Fallon et al., 1991). If strategies utilized in the treatment of OCD also can be successfully 
applied in hypochondriasis treatment, one might think that OCD treatment could improve 
symptoms of hypochondriasis.  
 
Metacognitions and symptoms of hypochondria 
The CBT-model is currently established as the leading conceptualization of 
hypochondriasis. Recently however, it’s been suggested that psychopathology due to 
disturbance in metacognitions might necessitate a different understanding of the condition 
(Bailey & Wells, 2013a, 2013b). Metacognition is known as the appraisal of thought content 
or cognitive processes (Flavell, 1979). Furthermore, metacognition is assumed to comprise 
knowledge (beliefs), processes, and strategies that appraise, monitor or control cognition 
(Wells, 2000). In other words, metacognitions reflect attitudes about one’s own cognitions 
such as believing that one should control thinking, that worrying is dangerous, or that one is 
bad for thinking certain thoughts. These attitudes will in turn affect how a person experiences 
their cognitive process, and strategies applied with the purpose of creating harmony between 
thoughts, and thoughts about thoughts. According to metacognitive theory, the cause of 
psychopathology is not to be found in the content of thought, but in the individual’s 
metacognitions.  
Metacognition is predicted to be particularly important for emotional distress in 
disorders characterized by uncontrollable cognition (Wells, 1995). OCD is a disorder 
presenting uncontrollable cognition, characterized by unwanted, recurrent, and persistent 
obsessions (APA, 1994). Thus, metacognitions should be important in the psychopathology of 
OCD, which also seems to be the case (Janeck, Calamari, Riemann, & Heffelfinger, 2003; 
Ladouceur et al., 1995; Ladouceur, Rheaume, & Aublet, 1997; Lopatka & Rachman, 1995; 
Rachman & de Silva, 1978; Solem, Håland, Vogel, Hansen, & Wells, 2009; Wells, 1995). 
Considering that metacognition is theorized especially influencing in disorders where 
uncontrollable cognition is prominent, the same should be true for hypochondriasis. 
Comparisons between metacognition and established hypochondriacal symptom 
correlates demonstrate that metacognition has superior predictive power over other influential 
variables in hypochondria (Bailey & Wells, 2013a). One study looked at somatosensory 
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amplification, illness cognition, and neuroticism relative to metacognition. An analogue 
sample of 351 completed a questionnaire battery revealing that metacognitions correlated 
significantly and positively with hypochondriacal symptoms. Three metacognitive 
dimensions, namely negative beliefs about the uncontrollability of thoughts and danger, 
cognitive confidence, and beliefs about the need for control, accounted better for substantial 
variance than the control variables. Moreover, controlling for metacognition also had a large 
effect on the strength of the relationship between cognition and hypochondriacal symptoms.  
A clinical case study provides preliminary evidence for the effectiveness of applying a 
metacognitive treatment protocol when treating hypochondriasis (Bailey & Wells, 2013b). 
Here, an A-B single case series methodology (N=4) with a six month follow up was 
implemented. Therapy was guided by a generic metacognitive therapy (MCT) treatment plan. 
The hypochondriacs’ metacognitions demonstrated clinically significant improvements after 
treatment, and MCT resulted in reduction of hypochondriacal symptoms. Patients maintained 
recovery status at follow up.   
A study investigating worry and metacognitions in hypochondriasis found 
hypochondriacals to be more concerned about the lack of control, and the excess of 
interference they experienced in relation to illness-worry (Bouman & Meijer, 1999). Meta-
worry appeared to be the best predictor for hypochondriasis, as well as an increased 
awareness of one’s thoughts. Superstitious beliefs about worry have also been revealed by 
worry being assumed to provide protection from “tempting fate” (Wells & Hackmann, 1993). 
In summary, existing research points towards metacognition as an important component in 
accounting for the psychopathology of both OCD and hypochondriasis. Thus, metacognition 
seems to be significant regardless of diagnosis, and possibly a sustaining factor in both 
disorders.  
 
Aims and hypotheses of the current study 
There are four aims of the present study. First, the intension is to further examine the 
prevalence of hypochondriacal symptoms in patients with OCD. Overall, most studies have 
addressed prevalence rate of OCD symptoms in patients with hypochondriasis, rather than the 
reverse comorbidity. Currently, studies examining the prevalence of hypochondriacal 
symptoms in patients with OCD are few with relatively small sample sizes. Existing findings 
are inconclusive, but the robust and most recent studies are consistent suggesting that the 
prevalence rate is in the range of 13-15%, and significantly higher than in controls. In light of 
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previous research, the first hypothesis in this study will be: There is a higher prevalence of 
symptoms of hypochondria in patients with OCD than in controls, and the prevalence rate is 
in the range of 13-15%.  
A second aim of the study is to explore whether patients’ obsessive-compulsive 
symptom levels after OCD treatment are affected by symptoms of hypochondriasis at 
treatment startup. This has not been done prior to the current study. However, regarding 
comorbidity effects of other Axis I disorders, comorbid hypochondriacal symptoms could 
have a similar influence. The hypothesis tested, will therefore be that comorbid symptoms of 
hypochondriasis in OCD patients predicts poorer OCD treatment outcome.  
Third, this paper aims to examine if changes in hypochondriacal symptoms follow 
OCD treatment. Due to lack of previous research on this matter, a hypothesis has not been 
formulated.  
The fourth and final purpose of the current study is to further investigate whether 
metacognitions is related to symptoms of hypochondria and if change in metacognitions is 
related to symptom reduction. Considering previous research suggesting that metacognition is 
related to, and plays an important role in hypochondria, we expect compatible findings. Thus, 
our last hypothesis is that metacognition is related to hypochondriacal symptoms, and 
furthermore, change in metacognitions is related to improvement in symptoms of 
hypochondria.  
 
 
Method 
Procedure 
The study was conducted in Norway, and included 313 patients with OCD, and 382 
community controls. Between 2007-2013, OCD patients were recruited mainly through 
referrals from general practitioners or psychiatric outpatient clinics. Whereas 216 of the 
patients were inpatients at St. Olav’s Hospital in Trondheim, 32 were outpatients from a 
multisite study on exposure and response prevention for OCD, and 63 were outpatients at 
Sørlandet Hospital in Kristiansand (Håland et al., 2010). The main criterion for inclusion in 
the study was having a primary diagnosis of OCD. At St. Olav’s Hospital, this was obtained 
with the Anxiety Disorder Interview Schedule (ADIS-IV; Brown, DiNardo, & Barlow, 1994), 
while the Structured Clinical Interview for DSM-IV (SCID-1; First, Spitzer, Gibbon, & 
Williams, 1995) was used at Sørlandet Hospital, and in the multisite study. The same 
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exclusion criteria were applied across patient groups. Furthermore, patients using anti-
obsessional medication were encouraged to maintain stable dosage levels throughout 
treatment. A description of the patient sample’s demographic information is provided in table 
1. Within the patient sample, 43.6% of the St. Olav’s patients, 47.8% of the multisite patients, 
and 40.3% of the patients at Sørlandet received disability benefits. The remaining patients 
were either full-time students, part-time students, working full-time or part-time. The data 
collection was conducted by having patients fill out self-report inventories pre, and post-
treatment. Participants were measured on OCD symptoms, hypochondriacal symptoms, 
depressive symptoms, and metacognitive domains considered important in exploring, and 
conceptualizing psychopathological processes.  
Healthy controls were recruited through social media. The author encouraged 
acquaintances to respond to an internet survey consisting of the Yale –Brown Obsessive-
Compulsive Scale-Self-Report (Y-BOCS-SR), the Whiteley Index (WI), and the 
Metacognitions Questionnaire (MCQ-30). Of the 453 participants responding to the 
invitation, 382 completed the WI, 326 the MCQ-30, and 280 the Y-BOCS. A description of 
the control sample’s demographic information is provided in table 1. Among the controls, 
45.5% were full time students, 43.5% in full time jobs, and 0.2% were retired. Furthermore, 
8.8% were either in part time jobs or preoccupied with part time studies, while 2.0 % received 
disability benefits. In addition to the demographic descriptions of both patient and control 
sample, table 1 presents a comparison of the samples.  
 
Table 1 
Demographic Descriptions and Comparisons of the Patient and Control Sample 
 OCD Controls p 
N 313 453  
Age 34.55 (11.98) 26.15 (5.72) .000 
Age at debut of OCD 18.50 (9.41)   
Female gender 65.4% 55.2% .000 
Civil status   .000 
   Single 51.9% 42.6%  
   Married/cohabitant 44.0% 56.5%  
   Separated/divorced 4.1% 0.9%  
Disability benefits 40.3-47.8% 2.0% .000 
Note: OCD = Obsessive-Compulsive Disorder. 
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Treatment and therapists 
Patients were enrolled in different treatment programs based on exposure and response 
prevention (ERP) for OCD (Foa & Kozak, 1997). These programs involved psycho-
education, construction of a symptom hierarchy, ERP, and maintenance/relapse prevention. 
However, the treatment was given in different formats. The majority of St. Olavs patients 
received inpatient treatment, those from Sørlandet Hospital underwent outpatient group 
therapy, and the multisite patients were given outpatient treatment. The group therapy was 
based on a manual on OCD group therapy, developed by Krone, Himle, and Nesse (1991). 
The therapists were all trained in ERP, and consisted of mainly psychologists, but also 
psychiatrists, and psychiatric nurses. 
 
Measures 
OCD-symptoms. OCD symptoms were measured with the Yale-Brown Obsessive-
Compulsive Scale (Y-BOCS; Goodman et al., 1989a) or the Yale-Brown Obsessive-
Compulsive Scale-Self-Report (Y-BOCS-SR; Baer, Brown-Beasley, Sorce, & Henriques, 
1993; Steketee, Frost, & Bogart, 1996). Y-BOCS is a clinician-rated scale measuring severity 
of cardinal symptoms of OCD along dimensions of time, interference, distress, resistance, and 
control. The scale has ten items, and a two-factor structure (obsessions, and compulsions). 
Each item is rated from 0-4, higher numerical score corresponding to greater illness severity. 
This makes the total range 0-40. Only total scores were used in our study. Y-BOCS has good 
psychometric properties in terms of being a reliable, and valid instrument for assessing OCD 
symptom severity (Goodman et al.,1989a, 1989b) and is considered the gold standard 
assessment for this purpose (Grabill et al., 2008).  
The Y-BOCS-SR (Baer et al., 1993; Steketee et al., 1996) is a reliable and valid 
measure (Steketee et al., 1996), derived from the clinician-administered version (Goodman et 
al.,1989a, 1989b). The Y-BOCS-SR instrument is designed with the same items and scoring 
system as Y-BOCS. Pearson correlations for the total score between Y-BOCS-SR and Y-
BOCS interview version (Goodman et al., 1989a, 1989b) were 0.79 in a clinical population, 
and 0.75 in a non-clinical population (Steketee et al., 1996). The psychometric properties of 
the Y-BOCS and the Y-BOCS-SR have not been assessed with Norwegian samples. The 
Cronbach’s alpha value for the total scale was .83 in the patient sample, and .87 in the control 
sample.   
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Hypochondria symptoms. The Whiteley Index (WI; Pilowsky, 1967) was utilized to 
measure hypochondriacal symptom severity. WI is a self-report questionnaire mapping 
hypochondriacal attitudes and beliefs. The scale comprises 14 items about worry and 
conviction about illness, attention to self and body, and reaction to doctor’s reassurance. 
Factor analysis has extracted a 3-factor structure, subscales being disease fear, disease 
conviction, and bodily preoccupation (Pilowsky, 1967). Responses are scored on a five-point 
Likert-scale, with a total score range of 14-70. High scores reflect a greater occurrence of 
hypochondriacal attitudes and beliefs (Barsky et al., 1992). The WI has shown to be satisfying 
regarding psychometric properties, with established test-retest reliability, internal consistency, 
and validity (Beaber & Rodney, 1984; Hanback & Revelle, 1978; Kasteler et al., 1976; 
Pilowsky, 1967, 1978). The total scores and a cutoff set to 40 were applied to detect probable 
hypochondriacals. This cutoff was based on a previous study where a cutoff at 40 
distinguished nearly all interview-diagnosed patients from controls (Noyes et al., 1993). The 
Cronbach’s alpha value for the total scale was .92 in the patient sample, and .89 in the control 
sample.   
Metacognitive dimensions. The Metacognitions Questionnaire (MCQ-30; Wells & 
Cartwright-Hatton, 2004) was used to measure metacognition. The MCQ-30 is a 30-item self-
report scale assessing a range of metacognitive domains considered important in exploring 
and conceptualizing psychopathological processes. These domains constitute positive beliefs 
about worry, negative beliefs about the controllability of thoughts and corresponding danger, 
cognitive confidence, negative beliefs about thoughts/need to control thoughts, and cognitive 
self-consciousness. Each of the 30 items has a four-point scale ranging from one to four. 
Higher scores reflect greater difficulties with the metacognitive dimension in question. The 
MCQ-30 possesses good internal consistency (Spada, Mohiveddini, & Wells, 2008) and 
convergent validity, as well as acceptable test-retest reliability (Wells & Cartwright-Hatton, 
2004). The Cronbach’s alpha value for the total scale was .92 in the patient sample, and .91 in 
the control sample.   
Depressive symptoms. Depressive symptoms were measured with the revised Beck 
Depression Inventory (BDI; Beck & Steer, 1993) or the Beck Depression Inventory-II (BDI-
II; Beck, Steer, & Brown, 1996). BDI is a self-report instrument consisting of 21 items, each 
employing a 4-point scale ranging from 0-3. Total scores range from 0-63, higher scores 
indicating greater depression symptomatology. BDI is a reliable and valid measure of 
depression severity (Beck, Steer & Garbin, 1988; Nuevo et al. (2009).  
BDI-II (Beck, Steer, & Brown, 1996) is an upgraded version of BDI. In general, the 
SYMPTOMS OF HYPOCHONDRIA IN OCD 
	  
15	  
psychometric characteristics of BDI-II are highly congruent with those of BDI, with the 
correlation between BDI and BDI-II being 0.93 in a non-clinical population, despite several 
instrument alterations in format and content (Dozois, Dobson, & Ahnberg, 1998). The 
psychometric properties of BDI-II have been replicated with a Norwegian non-clinical sample 
(Aasen, 2001). The Cronbach’s alpha value for the total scale was .83 in the patient sample. 
 
Overview of statistical analyses 
For the first analyses, the patient sample was compared to the control group on 
demographic variables using independent t-tests and one way ANOVA. Furthermore effect 
sizes and a paired samples t-test was utilized for evaluating treatment effect. To compare 
patients and controls on the different variables, independent t-tests were conducted, and 
correlation and regression analyses were used to investigate whether hypochondriacal 
symptoms in OCD patients affected symptoms of OCD after treatment. Finally, we calculated 
the correlation between metacognitions and symptoms, and rendered regression analyses to 
assess whether change in metacognition was related to treatment outcome measured with WI-
post-treatment.  
 
 
 
 
Results 
Prevalence 
Figure 1 and 2 illustrate the distribution of WI scores in the patient sample and control 
group respectively. The vertical line indicates the cut-off score of 40. Figure 1 shows that 
30.7% of the OCD patients scored above the suggested cut-off on WI total at pre-treatment. 
Figure 2 reveals a significantly lower hypochondriacal symptoms prevalence rate of 4.7% in 
the control group.  
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Figure 1. Hypochondriacal Symptoms in the OCD Sample                                  
 
Figure 1. The vertical line represents the cut-off score (>39) for the WI questionnaire 
detecting probable hypochondriasis.  
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Figure 2. Hypochondriacal Symptoms in the Control sample 
 
Figure 2. The vertical line represents the cut-off score (>39) for the WI questionnaire 
detecting probable hypochondriasis.  
 
 
 
Do symptoms of hypochondria affect OCD treatment outcome? 
Symptoms of pre-treatment hypochondria were almost significantly correlated with 
post-treatment Y-BOCS (r = .12, p = .053). A regression analysis controlling for Y-BOCS 
pre-treatment in step 1 suggested that pretreatment levels of OCD were significantly related to 
post-treatment Y-BOCS (Adj R square = .09, p = .000), while WI pre-treatment in step two 
did not add significantly to the equation (p = .257). In other words, there were no sign of 
hypochondriacal symptoms affecting OCD treatment outcome.  However, by transforming 
WI scores into z-scores, and comparing patients with ±1SDthere is a significant difference 
between the high WI and the low WI group (equal to an effect size of .56). Patients with high 
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scores exhibit poorer YBOCS post scores (13.2, [SD = 6.13]), while those with low cores get 
better results on YBOCS post (9.9, [SD = 5.7]). This means that patients with a high 
hypochondriasis symptom level at pre-treatment exhibit more symptoms of OCD after OCD 
treatment, compared with those who have less symptoms of hypochondria at treatment start. 
 
 
Changes in hypochondria symptoms following OCD treatment 
Overall, the results showed a significant decrease in all variables after treatment. OCD 
treatment was effective in reducing OCD symptoms, as documented by a large effect size (d = 
2.12). Results also revealed significant changes with large effect sizes in depressive 
symptoms (d = 1.22) and metacognitions (d = 1.25) following treatment. For all variables, 
there was found a significant difference between the samples. Table 2. Illustrates sample 
comparison and treatment effects on symptoms and beliefs. 
The share of participants exhibiting WI scores above cutoff went from 30.7% before 
treatment to 9.0% after treatment in the OCD sample. Effect size calculations suggested that 
symptoms of hypochondria changed moderately (d = .60) following OCD treatment. Paired 
samples t-test suggested that these changes were significant. At post-treatment, the 
differences between the patient sample and the control sample were relatively small (d = .25). 
Paired samples t-test for WI scores from post-treatment to follow-up suggested that the 
changes in hypochondria symptoms were stable (p = .892).  
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Table 2  
Sample Comparison and Treatment Effects on Symptoms and Beliefs 
 Controls OCD Controls vs. OCD Pre-post 
  pre post p d p d 
WI 23.27 
(7.65) 
33.16 
(12.14) 
25.85 
(12.31) 
.000 .97 .000 .60 
WI* 4.7% 30.7% 9.0%     
Y-BOCS 3.74 
(4.64) 
24.55 
(5.31) 
11.95 
(6.49) 
.000 4.17 .000 2.12 
BDI 
n. a. 
17.75 
(9.68) 
7.18 
(7.46) 
  .000 1.22 
MCQ 48.99 
(12.31) 
66.01 
(16.21) 
47.05 
(14.10) 
.000 1.18 .000 1.25 
Pos 8.77 
(3.12) 
9.96 
(4.31) 
7.91 
(3.00) 
.000 .32 .000 .55 
Neg 10.19 
(3.52) 
15.62 
(4.20) 
9.87 
(3.66) 
.000 1.40 .000 1.46 
CC 9.37 
(3.36) 
12.21 
(4.81) 
9.73 
(3.89) 
.000 .68 .000 .57 
Control 9.36 
(3.15) 
13.26 
(4.43) 
8.65 
(3.06) 
.000 1.01 .000 1.21 
CSC 11.31 
(3.58) 
14.96 
(4.39) 
10.88 
(4.17) 
.000 .91 .000 .95 
Note: WI = Whiteley Index, WI* = percentage above WI cutoff score, Y-BOCS = Yale-Brown Obsessive 
Compulsive Scale,  BDI = Beck Depression Index, MCQ =Metacognitive Questionnaire , Pos = Positive beliefs, 
Neg = Negative beliefs, CC = Cognitive confidence, Control = Need to control thoughts, CSC = Cognitive self-
consciousness. 
 
 
Metacognitions in symptoms of hypochondria and OCD 
As can be seen in table 3, pre-treatment correlations suggested that WI was 
moderately correlated with depression and metacognitions. All metacognitive dimensions 
were positively correlated with symptoms of hypochondriasis. The dimension “beliefs about 
the controllability of thoughts and corresponding danger” had the highest correlation with WI. 
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“Need to control thoughts” had the second highest correlation, while “cognitive confidence” 
and WI were most weakly correlated. Y-BOCS showed a weak positive correlation with WI, 
and a weak to moderate positive correlation with metacognitions. The correlations showed a 
similar pattern at post-treatment. Change-score correlations revealed similar patterns and 
changes in metacognition were related to both changes in symptoms of OCD, depression, and 
hypochondriasis. Y-BOCS scores at post-treatment were more strongly correlated with the 
other measures than at pre-treatment, probably due to increase in range of Y-BOCS scores. 
The correlation patterns observed in the patient sample were similar to the pattern observed in 
the control sample as displayed in table 4. 
A regression analysis entering WI pre at step 1 and MCQ change on step two 
suggested that pre-treatment levels of hypochondria explained 35.5% of the variance in post-
treatment WI. Changes in metacognition added significant variance and explained an 
additional 11.8% of post-treatment scores in WI. Adjusted R square for the model was .47.  
 
Table 3  
Correlations Between Symptoms and Metacognitive Beliefs in the OCD Sample 
Pre-treatment correlations 
 WI Y-BOCS BDI MCQ Pos Neg CC Control CSC 
WI  .16** .43** .46** .31** .48** .23** .39** .30** 
Y-BOCS   .34** .26** .13* .35** .09ns .24** .18** 
BDI    .42** .17** .40** .30** .40** .27** 
Post-treatment correlations 
WI  .33* .41** .49** .35** .47** .33** .41** .36** 
Y-BOCS   .50** .59** .37** .62** .40** .47** .45** 
BDI    .52** .32** .51** .41** .42** .39** 
Change-score correlations 
WI  .25** .38** .48** .14ns .44** .35** .34** .41** 
Y-BOCS   .33** .38** .14* .43** .25** .22** .33** 
BDI    .46** .15* .34** .41** .45** .33** 
Note. WI = Whiteley Index, Y-BOCS = Yale-Brown Obsessive Compulsive Scale, BDI = Beck Depression 
Index, MCQ =Metacognitive Questionnaire , Pos = Positive beliefs, Neg = Negative beliefs, CC = Cognitive 
confidence, Control = Need to control thoughts, CSC = Cognitive self-consciousness, * = p < 0.05, ** =  p < 
0.01. 
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Table 4  
Correlations Between Symptoms and Metacognitive Beliefs in the Control Sample 
 Y-BOCS MCQ Pos Neg CC Control CSC 
WI .43 .47 .22 .53 .23 .37 .35 
Y-BOCS  .56 .43 .55 .27 .41 .39 
Note. WI = Whiteley Index, Y-BOCS = Yale-Brown Obsessive Compulsive Scale, MCQ =Metacognitive 
Questionnaire , Pos = Positive beliefs, Neg = Negative beliefs, CC = Cognitive confidence, Control = Need to 
control thoughts, CSC = Cognitive self-consciousness, p = <0.01 for all correlations. 
 
 
 
Discussion 
Prevalence of symptoms of hypochondriasis in patients with OCD 
Symptoms of hypochondria were more common in OCD patients compared with that 
of the community sample. However, results revealed a prevalence rate of 30.7%, which is 
more than twice as high as foreseen based on previous research (Jaisoorya et al., 2003; 
Bienvenu et al., 2000).  
Perhaps the WI cut-off applied in this study detecting probable hypochondriacals was 
set too low, creating a falsely high prevalence of hypochondriacal tendencies among the 
participants. On the other hand, the cutoff in this trial was based on the one set in a previous 
study where the researchers successfully distinguished nearly all interview-diagnosed patients 
from controls (Noyes et al., 1993). In other words, the current cut-off should be relatively 
precise in detecting symptoms of hypochondria. 
 In the two previous studies that are emphasized here, SCID-I, K-SADS (Jaisoorya et 
al., 2003), and SADS-LA (Bienvenu et al., 2000) were used to measure hypochondriasis. It’s 
possible that the WI questionnaire generally tends to give a higher prevalence rate than the 
diagnostic interviews used in the other studies. According to Fallon et al. (1993), the WI 
questionnaire clearly detects fear of having a serious disease rather than fear of getting one in 
the future, which is one of the main differences between hypochondriasis and OCD. 
However, the results might be due to the WI separating poorly between hypochondriasis and 
health-related obsessions in OCD after all.   
Certain OCD subtypes seem to be more closely related to comorbid hypochondriasis 
than others (Lochner et al., 2005; Abramowitz, McKay, & Taylor, 2008). For example, 
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Abramowitz and colleagues (1999) compared OCD patients with and without health 
concerns. Results revealed that OCD patients with health concerns scored higher on 
contamination obsessions and washing compulsions, whereas the “pure” OCD patients were 
more engaged in harming obsessions and checking compulsions. Regarding this, an especially 
high share of the OCD subtype themed around contamination and decontamination in the 
patient group, would most likely contribute to increase the number of patients also exhibiting 
hypochondria.  
Another possible explanation for the high prevalence estimate could be that depressed 
individuals exhibit mood-congruent recall (Matt, Vàzquez, & Campbell, 1992). This means 
that stimuli of the same affective valence as their present mood are learned and retrieved 
better than stimuli of valence disagreeing with this mood. Thus, when depressed patients 
rapport their hypochondriacal symptoms, it’s possible that they’re biased towards an 
exaggerating reporting style creating inflated scores.  
Looking at the correlation between the hypochondriacal symptoms and other 
symptomatology, symptoms of hypochondria exhibited a closer relationship with depressive 
symptoms than those of OCD. It could be that the high prevalence rate is a result of high 
symptom pressure in general. Considering the previously mentioned similarities between 
hypochondriasis and OCD however, the disorders are likely to co-occur due to similar 
underlying mechanisms.   
 
Do symptoms of hypochondria affect OCD treatment outcome? 
Hypochondriasis was not found to affect OCD treatment outcome negatively. This is 
inconsistent with the general negative effects often found for comorbidity in treatment of 
emotional disorders and OCD more specifically (Abramowitz et al., 2000; Hansen et al., 
2007; Keeley et al., 2008; Steketee et al., 2001; Tükel et al., 2002). However, when 
comparing high and low scorers on the WI there was a difference in treatment outcome for the 
two groups similar to previous findings on the role of depression in OCD (Abramowitz et al., 
2000). Patients with high scores on the WI had significantly higher Y-BOCS post-treatment 
scores than the low group and these patients also exhibited higher symptom levels of OCD, 
depression, and metacognitions when starting treatment.  
Perhaps sub-clinical symptoms of hypochondriasis do not hinder OCD treatment while 
severe OCD- and hypochondriasis symptoms could interfere with treatment. This could be 
due to general symptoms severity and because of how the two disorders overlap and share 
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common underlying mechanisms such as metacognitions. As shown in this study both OCD 
and hypochondriasis were related to metacognitive beliefs which were significantly reduced 
following treatment. Also, as mentioned initially, hypochondriasis resembles OCD in that 
evocation and regulation of anxiety unfold much like obsessions and compulsions (Fallon et 
al., 1991; Neziroglu et al., 2000; Warwick & Salkovskis, 1990). Furthermore, the core 
characteristic of hypochondriasis (fear of illness) is a common theme of obsessions and 
compulsions (Savron et al., 1996). Taken together, this might make the patients with 
hypochondriasis symptoms able to generalize what they’ve learned about dealing with 
intrusive thoughts and coping strategies.  
 
Changes in hypochondriacal symptoms following OCD treatment 
The findings suggest a significant improvement in hypochondriacal symptoms of 
moderate strength following OCD treatment. This is in line with numerous controlled studies 
have shown that manual based treatment directed towards treating one particular disorder can 
lead to symptom improvement in other disorders as well (Wilson, 1997). As mentioned 
previously, there are significant overlaps between hypochondriasis and OCD (Fallon et al., 
1991; Neziroglu et al., 2000; Savron et al., 1996; Warwick & Salkovskis, 1990). Considering 
these overlaps, it’s possible that they might cause OCD treatment to be effective on 
hypochondriacal symptoms as well. The finding that symptoms of hypochondria and OCD are 
both related to metacognitions is in line with metacognitive theory as one would expect that 
symptoms of emotional disorder decrease when dysfunctional metacognitive beliefs are 
adjusted. Another possible explanation for these findings is that health related intrusions and 
behaviours have been addressed during the treatment. This might be due to health personnel 
viewing hypochondriacal symptoms as part of- or related to the OCD. 
 
Metacognitions in symptoms of hypochondrias and OCD 
Hypochondriacal symptoms were moderately correlated with metacognition, and 
changes in metacognitions explained of a significant proportion of hypochondriacal 
symptoms at post-treatment. These results correspond with existing research (Bailey & Wells, 
2013a, 2013b; Bouman & Meijer, 1999; Solem et al., 2009; Wells & Hackman, 1993). Two 
particular metacognitive domains that could be relevant in a metacognitive model of 
hypochondriasis were identified. These are “negative beliefs about thoughts concerning 
uncontrollability and danger”, and “negative beliefs concerning the consequences of not 
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controlling thoughts”. The strong correlations between these two metacognitive dimensions 
and hypochondria is in accordance with the previous study reporting hypochondriacals to be 
more concerned about the lack of control, and the excess of interference experienced in 
relation to worry (Bouman & Meijer, 1999). However, here hypochondriasis was found to be 
a dimension best predicted by specific meta-worries about lack of control over thoughts about 
illness, as well as a cognitive self-consciousness, suggesting the existence of disorder-spesific 
meta-worries.  
The design of this study does not allow for conclusions concerning causality between 
change in metacognitions and symptom improvements during treatment. In accordance with 
the metacognitive model (Wells, 2000), improvement in metacognitions might have lead to 
improvement in hypochondriacal symptoms. It could however, be that improvements in 
symptoms of hypochondriasis post OCD treatment caused a change in metacognitions. Also, 
an undetected/unknown factor accounting for both reduction of hypochondriasis symptoms 
and improved metacognitive functioning might be present.  
 
Strengths and limitations 
The strengths in this study were that diagnostic interviews were applied detecting 
OCD before inclusion in the patient sample, that there was a relatively large sample size, that 
a community group matching the size of the patient group was applied, and that two out of 
four problem formulations had not been addressed in previous research.  
Limitations are that no conclusions about causation can be made, that data were 
collected using self-report measures, and that follow-up data were not included. Furthermore, 
the control group was a convenience sample, which did not match the patient sample 
demographically. Other limitations are that the study also lacked a control group with a 
different psychopathology, that our patient sample consisted of patients from three different 
ERP-treatment programs, and that there was no adherence measurement. A final limitation of 
these findings is that the diagnoses described in the present study were based on DSM-4, 
rather than DSM-5 criteria (APA, 2013). Diagnostic criteria for OCD did not change 
appreciably from one edition to the next, but the diagnosis of hypochondriasis has been 
eliminated as a disorder. Two diagnoses, namely illness anxiety disorder and somatic 
symptoms disorder are assumed to cover the former hypochondriasis diagnosis (Changes 
DSM 5). Because these are new as of DSM-5, we cannot be sure of the transfer value of the 
research that’s been done in this thesis. 
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Conclusion and Clinical Implications 
The present study confirms that there is a relatively high occurrence of comorbid 
hypochondriasis in OCD. This implies that future research is needed to further examine how 
hypochondriasis and OCD affect each other, whether they can be explained by common 
mechanisms, and how knowledge on these matters can contribute to efficient treatment of 
both OCD and hypochondriasis. Findings suggest that patients enrolled in OCD treatment 
programs seem able to profit from treatment despite having comorbid hypochondriasis, unless 
the degree of hypochondriasis is fairly severe. In fact, most patients receiving treatment for 
their OCD who also suffer from hypochondriasis actually seem to exhibit improvements in 
both conditions. This suggests that there might be common mechanisms causing both OCD 
and hypochondriasis, and considering the results of the current study, these mechanisms 
might take the form of metacognitions. The clinical implications of these findings are that 
comorbid hypochondriasis should not be an exclusion criteria from being enrolled in OCD 
treatment, except for cases of particularly severe hypochondriasis where enrollment is 
dissuaded. Actually, if a person suffers from both OCD and symptoms of hypochondriasis, 
OCD treatment could be cost effective considering that both conditions might improve. 
Furthermore, examining and focusing on improving metacognitions in patients with OCD, 
hypochondriasis or both is adviced.  
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